The approval was based on data from two phase 3 trials that evaluated the use of Cosentyx in patients 6 ... modified 2011 score of ‘clear’ or ‘almost clear’ (0 or 1) with at least a ...

In addition, a larger percentage of patients in the Cosentyx group achieved an IGA (Investigator’s Global Assessment) scalp only score of 0 or 1 (clear or almost clear) vs the placebo group (56. ...

Late-breaking data at EADV show that 8 out of 10 of psoriasis patients (83%) achieved 75% skin clearance (PASI 75) with Cosentyx TM after three years[1] 6 out of 10 patients (64%) had clear or ...

With Eli Lilly's IL-17 competitor, Taltz, entering the psoriasis market in March 2016 and the PsA landscape nearly two years later, it became clear that Cosentyx's first-in-class status provided ...

"Cosentyx is the first and only IL-17A antagonist approved for psoriasis, psoriatic arthritis and ankylosing spondylitis and has been prescribed to more than 100,000 patients since launch." Clear ...

After two full years of therapy, 7 out of 10 (71%) patients treated with Cosentyx 300 mg had clear or almost clear skin (PASI 90); 4 out of 10 (44%) had clear skin (PASI 100) and almost 9 out of ...

76% for Cosentyx vs 61% for Stelara at 52 weeks. This head-to-head CLEAR study was published in advance of the EADV congress in the Journal of the American Academy of Dermatology. Further data ...

Results of the CLEAR study showing Cosentyx is better at clearing skin than Stelara first emerged at the European Academy of Dermatology and Venerology (EADV) conference in October. Data presented ...

The label update includes 52-week data from the CLEAR study which demonstrated the long-term superiority of Cosentyx over Johnson & Johnson's JNJ Stelara (ustekinumab) in psoriasis. The study ...

That trial tested four dose levels of sonelokimab against placebo and Novartis’ Cosentyx. RELATED ... More patients taking the nanobody achieved clear or almost clear skin, as measured by ...